BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31690178)

  • 1. Changes in the incidence of cervical tumours by disease stage in a cytology-based screening programme.
    Bucchi L; Mancini S; Baldacchini F; Giuliani O; Ravaioli A; Vattiato R; Falcini F; Giorgi Rossi P; Campari C; Canuti D; Di Felice E; de Bianchi PS; Ferretti S;
    J Med Screen; 2020 Jun; 27(2):96-104. PubMed ID: 31690178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
    BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.
    Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LC; Cuzick J; Myers O; Castle PE; Wheeler CM;
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):36-42. PubMed ID: 26518316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China.
    Pan QJ; Hu SY; Zhang X; Ci PW; Zhang WH; Guo HQ; Cao J; Zhao FH; Lytwyn A; Qiao YL
    Cancer Cytopathol; 2013 Sep; 121(9):473-82. PubMed ID: 23907807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
    Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
    JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance indicators of organized cervical screening in Romagna (Italy).
    Bucchi L; Falcini F; Schincaglia P; Desiderio F; Bondi A; Farneti M; Casadei Giunchi D; Serafini M; Canuti D; Caprara L; Sabbadini F; Monari F; Sassoli P
    Eur J Cancer Prev; 2003 Jun; 12(3):223-8. PubMed ID: 12771561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
    Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
    Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Human Papilloma Virus (HPV), cervical cancer incidence and screening uptake: differences among Northern, Central and Southern Italy].
    Giorgi Rossi P; Chini F; Borgia P; Guasticchi G; Carozzi FM; Confortini M; Angeloni C; Buzzoni C; Buonaguro FM;
    Epidemiol Prev; 2012; 36(2):108-19. PubMed ID: 22706361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of Atypical Squamous Cells of Undetermined Significance among Patients Undergoing Cervical Conization.
    Nishimura M; Miyatake T; Nakashima A; Miyoshi A; Mimura M; Nagamatsu M; Ogita K; Yokoi T
    Asian Pac J Cancer Prev; 2015; 16(18):8145-7. PubMed ID: 26745052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening history of cervical cancers in Emilia-Romagna, Italy: defining priorities to improve cervical cancer screening.
    Rossi PG; Caroli S; Mancini S; de' Bianchi PS; Finarelli AC; Naldoni C; Bucchi L; Falcini F;
    Eur J Cancer Prev; 2015 Mar; 24(2):128-34. PubMed ID: 24787379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of abnormal cervical and vaginal cytology among women over age 65 years living with human immunodeficiency virus.
    Stewart KA; Allen SM; Chesnokova AE; Syed F; Levison JE
    Am J Obstet Gynecol; 2020 May; 222(5):486.e1-486.e10. PubMed ID: 31678094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.
    Leinonen MK; Nieminen P; Lönnberg S; Malila N; Hakama M; Pokhrel A; Laurila P; Tarkkanen J; Anttila A
    BMJ; 2012 Nov; 345():e7789. PubMed ID: 23197596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study.
    Wang J; Andrae B; Sundström K; Ström P; Ploner A; Elfström KM; Arnheim-Dahlström L; Dillner J; Sparén P
    BMJ; 2016 Feb; 352():i276. PubMed ID: 26869597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of cervical screening after age 60 years according to screening history: Nationwide cohort study in Sweden.
    Wang J; Andrae B; Sundström K; Ploner A; Ström P; Elfström KM; Dillner J; Sparén P
    PLoS Med; 2017 Oct; 14(10):e1002414. PubMed ID: 29065127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive cervical cancer and screening: what are the rates of unscreened and underscreened women in the modern era?
    Subramaniam A; Fauci JM; Schneider KE; Whitworth JM; Erickson BK; Kim K; Huh WK
    J Low Genit Tract Dis; 2011 Apr; 15(2):110-3. PubMed ID: 21263352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
    Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
    Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid-based cytology and conventional cervical smears: a comparison study in an Asian screening population.
    Cheung AN; Szeto EF; Leung BS; Khoo US; Ng AW
    Cancer; 2003 Dec; 99(6):331-5. PubMed ID: 14681939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening frequency and atypical cells and the prediction of cervical cancer risk.
    Chen YY; You SL; Koong SL; Liu J; Chen CA; Chen CJ;
    Obstet Gynecol; 2014 May; 123(5):1003-1011. PubMed ID: 24785853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.